Structural Formula For Clopidogrel Bisulfate (89033966 72f2 44b3 8335 3d12e82f27fe 01)
Clopidogrel
Product Images NDC 66116-494
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 66116-494). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (89033966 72f2 44b3 8335 3d12e82f27fe 02)
This text describes the effect of coadministered PPT including Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole in different doses ranging from 30-80mg, on the active metabolite AUC. It provides statistical data in the form of mean and 90% confidence interval, however, the context and outcome of the study are not mentioned.*
Figure 2 (89033966 72f2 44b3 8335 3d12e82f27fe 03)
This text appears to be a table showing the cumulative event rate of cardiovascular death, myocardial infarction, and stroke for two groups: one group that received placebo and aspirin, and another group that received clopidogrel and aspirin. The text mentions that other standard therapies were used as appropriate. The results show a statistically significant difference between the two groups (p=0.000008). The duration of follow-up appears to have been several months (indicated by "MONTHS OF FOLLOW:LP").*
Figure 3 (89033966 72f2 44b3 8335 3d12e82f27fe 04)
Figure 3: Cumulative Event Rates For Death In The Commit Study (89033966 72f2 44b3 8335 3d12e82f27fe 05)
This text appears to be presenting statistical data related to a medical study comparing two treatments (a placebo and Clopidogre) and their impact on mortality (death). The study observed a 7% reduction in risk of death with the use of Clopidogre, which was statistically significant (p=0.03), during the 28 days after randomization. There is no further context to summarize.*
Figure 5 (89033966 72f2 44b3 8335 3d12e82f27fe 06)
The text appears to be a comparison of placebo and clopidogrel treatment in reducing the risk of death, reinfarction, or stroke before discharge, with data presented on the number of events and proportional risk reduction. The timeline is also mentioned, with measurements taken up to 28 days since randomization.*
Figure 6 (89033966 72f2 44b3 8335 3d12e82f27fe 07)
The provided text is a statistical data table that includes baseline events, odds ratio, and heterogeneity values in the context of Clopidogrel and Placebo categories. The table also shows percentages of different factors such as sex, age at entry, systolic blood pressure, heart rate, and prognostic index. It includes Metoprolol allocation statistics and a global heterogeneity test. Therefore, it is a statistical data table and not a useful description.*
Figure 7 (89033966 72f2 44b3 8335 3d12e82f27fe 08)
This text appears to be a statistical analysis report of events, odds ratio, and heterogeneity for a study that investigated the efficacy of Clopidogrel compared to Placebo in patients with various conditions such as Killip class, previous MI, and infarct location. The report includes tables of results such as odds ratios and confidence intervals, as well as statistical tests for heterogeneity.*
Figure 8 (89033966 72f2 44b3 8335 3d12e82f27fe 09)
The graph displays the cumulative event rate (in percentage) for fatal or non-fatal vascular events with the use of aspirin or clopidogrel. The months of follow-up are not available. The statistical significance of the difference in event rate between the two treatments is P=0.045.*
Clopidogrel 75mg Tablets #30 (89033966 72f2 44b3 8335 3d12e82f27fe 10)
This appears to be information related to medication dosage and delivery. The text suggests that there is a medication called "MedStart" available as tablets in a 75mg dosage. It also provides a phone number and website for home delivery of the medication, free of shipping charges. The text also lists the name of the manufacturer, Teva Pharmaceuticals USA.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
